These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 36776497)

  • 41. Anti-IP-10 antibody (BMS-936557) for ulcerative colitis: a phase II randomised study.
    Mayer L; Sandborn WJ; Stepanov Y; Geboes K; Hardi R; Yellin M; Tao X; Xu LA; Salter-Cid L; Gujrathi S; Aranda R; Luo AY
    Gut; 2014 Mar; 63(3):442-50. PubMed ID: 23461895
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
    Wang Y; Parker CE; Bhanji T; Feagan BG; MacDonald JK
    Cochrane Database Syst Rev; 2016 Apr; 4(4):CD000543. PubMed ID: 27101467
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
    Feagan BG; Macdonald JK
    Cochrane Database Syst Rev; 2012 Oct; 10():CD000543. PubMed ID: 23076889
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis.
    Colombel JF; Rutgeerts P; Reinisch W; Esser D; Wang Y; Lang Y; Marano CW; Strauss R; Oddens BJ; Feagan BG; Hanauer SB; Lichtenstein GR; Present D; Sands BE; Sandborn WJ
    Gastroenterology; 2011 Oct; 141(4):1194-201. PubMed ID: 21723220
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Anrukinzumab, an anti-interleukin 13 monoclonal antibody, in active UC: efficacy and safety from a phase IIa randomised multicentre study.
    Reinisch W; Panés J; Khurana S; Toth G; Hua F; Comer GM; Hinz M; Page K; O'Toole M; Moorehead TM; Zhu H; Sun Y; Cataldi F
    Gut; 2015 Jun; 64(6):894-900. PubMed ID: 25567115
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Novel Bioenhanced Curcumin With Mesalamine for Induction of Clinical and Endoscopic Remission in Mild-to-Moderate Ulcerative Colitis: A Randomized Double-Blind Placebo-controlled Pilot Study.
    Banerjee R; Pal P; Penmetsa A; Kathi P; Girish G; Goren I; Reddy DN
    J Clin Gastroenterol; 2021 Sep; 55(8):702-708. PubMed ID: 32889959
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial.
    Vermeire S; O'Byrne S; Keir M; Williams M; Lu TT; Mansfield JC; Lamb CA; Feagan BG; Panes J; Salas A; Baumgart DC; Schreiber S; Dotan I; Sandborn WJ; Tew GW; Luca D; Tang MT; Diehl L; Eastham-Anderson J; De Hertogh G; Perrier C; Egen JG; Kirby JA; van Assche G; Rutgeerts P
    Lancet; 2014 Jul; 384(9940):309-18. PubMed ID: 24814090
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Infliximab for induction and maintenance therapy for ulcerative colitis.
    Rutgeerts P; Sandborn WJ; Feagan BG; Reinisch W; Olson A; Johanns J; Travers S; Rachmilewitz D; Hanauer SB; Lichtenstein GR; de Villiers WJ; Present D; Sands BE; Colombel JF
    N Engl J Med; 2005 Dec; 353(23):2462-76. PubMed ID: 16339095
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A Phase 1b Safety Study of SER-287, a Spore-Based Microbiome Therapeutic, for Active Mild to Moderate Ulcerative Colitis.
    Henn MR; O'Brien EJ; Diao L; Feagan BG; Sandborn WJ; Huttenhower C; Wortman JR; McGovern BH; Wang-Weigand S; Lichter DI; Chafee M; Ford CB; Bernardo P; Zhao P; Simmons S; Tomlinson AD; Cook DN; Pomerantz RJ; Misra BK; Auninš JG; Trucksis M
    Gastroenterology; 2021 Jan; 160(1):115-127.e30. PubMed ID: 32763240
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Unfractionated or low-molecular weight heparin for induction of remission in ulcerative colitis.
    Chande N; Wang Y; McDonald JW; MacDonald JK
    Cochrane Database Syst Rev; 2015 Aug; 8(8):CD006774. PubMed ID: 35658167
    [TBL] [Abstract][Full Text] [Related]  

  • 51. One-year maintenance outcomes among patients with moderately-to-severely active ulcerative colitis who responded to induction therapy with adalimumab: subgroup analyses from ULTRA 2.
    Sandborn WJ; Colombel JF; D'Haens G; Van Assche G; Wolf D; Kron M; Lazar A; Robinson AM; Yang M; Chao JD; Thakkar R
    Aliment Pharmacol Ther; 2013 Jan; 37(2):204-13. PubMed ID: 23173821
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy and safety of a new vedolizumab subcutaneous formulation in Japanese patients with moderately to severely active ulcerative colitis.
    Kobayashi T; Ito H; Ashida T; Yokoyama T; Nagahori M; Inaba T; Shikamura M; Yamaguchi T; Hori T; Pinton P; Watanabe M; Hibi T
    Intest Res; 2021 Oct; 19(4):448-460. PubMed ID: 32806876
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Long-term Safety and Efficacy of the Anti-MAdCAM-1 Monoclonal Antibody Ontamalimab [SHP647] for the Treatment of Ulcerative Colitis: The Open-label Study TURANDOT II.
    Reinisch W; Sandborn WJ; Danese S; Hébuterne X; Kłopocka M; Tarabar D; Vaňásek T; Greguš M; Hellstern PA; Kim JS; Sparrow MP; Gorelick KJ; Hoy M; Goetsch M; Bliss C; Gupta C; Cataldi F; Vermeire S
    J Crohns Colitis; 2021 Jun; 15(6):938-949. PubMed ID: 33599720
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy of probiotic treatment with Bifidobacterium longum 536 for induction of remission in active ulcerative colitis: A randomized, double-blinded, placebo-controlled multicenter trial.
    Tamaki H; Nakase H; Inoue S; Kawanami C; Itani T; Ohana M; Kusaka T; Uose S; Hisatsune H; Tojo M; Noda T; Arasawa S; Izuta M; Kubo A; Ogawa C; Matsunaka T; Shibatouge M
    Dig Endosc; 2016 Jan; 28(1):67-74. PubMed ID: 26418574
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Vedolizumab as induction and maintenance therapy for ulcerative colitis.
    Feagan BG; Rutgeerts P; Sands BE; Hanauer S; Colombel JF; Sandborn WJ; Van Assche G; Axler J; Kim HJ; Danese S; Fox I; Milch C; Sankoh S; Wyant T; Xu J; Parikh A;
    N Engl J Med; 2013 Aug; 369(8):699-710. PubMed ID: 23964932
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clinical trial: Effects of an oral preparation of mesalazine at 4 g/day on moderately active ulcerative colitis. A phase III parallel-dosing study.
    Hiwatashi N; Suzuki Y; Mitsuyama K; Munakata A; Hibi T
    J Gastroenterol; 2011 Jan; 46(1):46-56. PubMed ID: 20878425
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Methotrexate Is Not Superior to Placebo for Inducing Steroid-Free Remission, but Induces Steroid-Free Clinical Remission in a Larger Proportion of Patients With Ulcerative Colitis.
    Carbonnel F; Colombel JF; Filippi J; Katsanos KH; Peyrin-Biroulet L; Allez M; Nachury M; Novacek G; Danese S; Abitbol V; Bossa F; Moreau J; Bommelaer G; Bourreille A; Fumery M; Roblin X; Reinisch W; Bouhnik Y; Brixi H; Seksik P; Malamut G; Färkkilä M; Coulibaly B; Dewit O; Louis E; Deplanque D; Michetti P; Sarter H; Laharie D; ;
    Gastroenterology; 2016 Feb; 150(2):380-8.e4. PubMed ID: 26632520
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Randomised clinical trial: Efficacy and safety of Qing-Chang-Hua-Shi granules in a multicenter, randomized, and double-blind clinical trial of patients with moderately active ulcerative colitis.
    Shen H; Zhang S; Zhao W; Ren S; Ke X; Gu Q; Tang Z; Xie J; Chen S; Chen Y; Zou J; Zhang L; Shen Z; Zheng K; Liu Y; Gu P; Cheng J; Hu J; Zhu L
    Biomed Pharmacother; 2021 Jul; 139():111580. PubMed ID: 33857914
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Twice-daily Budesonide 2-mg Foam Induces Complete Mucosal Healing in Patients with Distal Ulcerative Colitis.
    Naganuma M; Aoyama N; Suzuki Y; Nishino H; Kobayashi K; Hirai F; Watanabe K; Hibi T
    J Crohns Colitis; 2016 Jul; 10(7):828-36. PubMed ID: 26577683
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Association Between Response to Etrolizumab and Expression of Integrin αE and Granzyme A in Colon Biopsies of Patients With Ulcerative Colitis.
    Tew GW; Hackney JA; Gibbons D; Lamb CA; Luca D; Egen JG; Diehl L; Eastham Anderson J; Vermeire S; Mansfield JC; Feagan BG; Panes J; Baumgart DC; Schreiber S; Dotan I; Sandborn WJ; Kirby JA; Irving PM; De Hertogh G; Van Assche GA; Rutgeerts P; O'Byrne S; Hayday A; Keir ME
    Gastroenterology; 2016 Feb; 150(2):477-87.e9. PubMed ID: 26522261
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.